乳清蛋白对非酒精性脂肪性肝病大鼠肝脂肪变的防治作用*

doi:10.3969/j.issn.1672-5069.2012.02.004

实用肝脏病杂志 ›› 2012, Vol. 15 ›› Issue (2): 89-92.doi: 10.3969/j.issn.1672-5069.2012.02.004

乳清蛋白对非酒精性脂肪性肝病大鼠肝脂肪变的防治作用^*

李莉, 钟乐萍, 赵斐, 展玉涛

100730北京市首都医科大学附属北京同仁医院消化科

收稿日期:2012-01-04 出版日期:2012-04-10 发布日期:2017-03-07
通讯作者: 展玉涛,E-mail：yutaozhan@263.net
作者简介:李莉女,30岁,医学硕士,医师。E-mail：doctorlili008@163.com
基金资助:
北京市自然科学基金项目（编号：7112032）

Protective effect of whey proteins on intrahepatic fatty infiltration in rats with nonalcoholic fatty liver disease

Li Li, Zhong Leping, Zhao Fei, et al.

Departement of Gastroenterology. Tongren Hospital,Affiliated to Capital Medical University,Beijing 100730,China

Received:2012-01-04 Online:2012-04-10 Published:2017-03-07

摘要/Abstract

摘要： 目的观察乳清蛋白（WP）对大鼠非酒精性脂肪性肝病（NAFLD）的防治作用。方法将35只SD大鼠随机分成对照组、模型组和治疗组,后者是在给予高脂饲料喂养的同时加用WP液灌胃干预,6周后观察各组大鼠体重、肝重、肝指数、丙氨酸氨基转移酶（ALT）、门冬氨酸氨基转移酶（AST）、甘油三酯（TG）、总胆固醇（TC）以及肝组织学改变。结果模型组大鼠肝组织病理学检查显示明显脂肪变,脂肪变积分为2.8±0.4,NAFLD活动度积分（NAS）为6.2±0.9,均明显高于对照组（0.8±0.5,P<0.01及0.9±0.7,P<0.01）;动物体重、肝重、肝指数和生化指标均高于对照组,其中肝指数为3.5±0.2,ALT为42.4±7.5u/l,差别有统计学意义（P<0.01）;与模型组比,治疗组动物体重和生化指标均有改善,其中ALT为34.8±5.6U/l和TG为0.2±0.1mmol/l,明显低于模型组（分别为42.4±7.5U/l,P<0.01和0.6±0.5mmol/l,P<0.05）;肝细胞脂肪变积分为1.6±0.9,NAS为2.9±1.4,也明显下降（P<0.01）。结论 WP对NAFLD大鼠肝脂肪变有防治作用,可能与改善血脂代谢,减少肝脏脂质沉积以及抑制肝脏炎症反应有关。

关键词: 非酒精性脂肪性肝病, 乳清蛋白, 非酒精性脂肪性肝病活动度积分, 大鼠

Abstract: Objective To investigate the influence of whey proteins （WP） on serum lipid metabolism and hepatic fatty infiltration changes in rats with nonalcoholic fatty liver disease（NAFLD）. Methods 35 SD rats were randomly divided into control （n=12）,model （n=11） and the therapeutic groups （n=12）. The control group were fed with normal diet,and the other two groups were fed with high-fat diet.Meanwhile,the therapeutic group were treated with WP（100mg/ml,0.5ml/d）. All rats were sacrificed at the end of six weeks.The pathological changes in livers in all rats were pathologically evaluated with HE stain,and the serum biochemistry index was also measured. Results Compared with the control group,the degree of fatty and inflammation were more serious in the model group,while oral administration of WP reduced the final body and liver weights of rats;the alanine transaminase was 34.8±5.6U/l,and serum triglyceride level was 0.2±0.1mmol/l in WP group,obviously reduced as compared to those in model group;liver histology showed an improvement of fatty infiltration in therapeutic group;the NAFLD activity score was significantly improved from 6.2±0.9 to 2.9±1.4（P<0.01） in WP group. Conclusions The obtained Results indicate that WP play a possible role in the regulation of liver biochemistries in the rat with NAFLD.The regulatory effect of WP is accompanied by an improvement in fatty infiltration and hepatic inflammation.

Key words: NAFLD, Whey proteins, NAFLD activity score, Rats

李莉, 钟乐萍, 赵斐, 展玉涛. 乳清蛋白对非酒精性脂肪性肝病大鼠肝脂肪变的防治作用^*[J]. 实用肝脏病杂志, 2012, 15(2): 89-92.

Li Li, Zhong Leping, Zhao Fei, et al.. Protective effect of whey proteins on intrahepatic fatty infiltration in rats with nonalcoholic fatty liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2012, 15(2): 89-92.

参考文献

[1] Qin Y,Tian Y. Preventive effects of chronic exogenous growth hormone levels on diet-induced hepatic steatosis in rats. Lipids Health Dis,2010,9:78.
[2] Essam M,Soad H,Abdel-Gawad I,et al. Protective effect of whey proteins against nonalcoholic fatty liver in rats. Lipids Health Dis,2011,10:57.
[3] Frid AH,Nillson M,Holst J,et al. Effect of Whey on blood glucose and insulin response to composite breakfast and lunch meals in type 2 diabetic subjects. Am J Clin Nutr,2005,82:69-75.
[4] Belobra DP,Mcintosh GH,Owens JA.A high-whey-protein diet reduces body weight gain and alters insulin sensitivity to red meat in Wistar rats. J Nutr,2004,134:1454-1458.
[5] Sun X,Zemelm B. Leucine and calcium regulate fat metabolism and energy partitioning in murine adipocytes and muscle cells. Lipids,200742:297-305.
[6] Cota D,Proulx K,Smith BKA,et al. Hypothalamic mTOR signaling regulates food intake. Science,2006,312:927-930.
[7] Lieber CS,Leo MA,Mak KM,et al. Model of nonalcoholic steatohepatitis. Am J Clin Nutrit,2010,7（8）:502-509.
[8] 中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南. 胃肠病学和肝病学杂志,2010,19（6）:483-487.
[9] 曾民德. 非酒精性脂肪性肝病研究的关切点.肝脏,2009,14:321-324.
[10] Farrell GC,Chitturi S,Lau GK,et al. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region:executive summary. J Gastroenterol Hepatol,2007,22:775-777.
[11] Day CP,James OF. Hepatic steatosis: inncent bystander or guilty party. Hepatology,1998,27（6）:1463-1466.
[12] Brody ER. Biological activities of bovine glycomacropeptide. Brit J Nutr,2000,84:S39-46.
[13] Paul A. Nonalcoholic fatty liver disease. N Engl J Med,2002,346（16）:1221-1231.
[14] 刘安楠,朱玲. 非酒精性脂肪性肝病患者脂代谢异常和胰岛素抵抗调查. 实用肝脏病杂志,2009,6（12）:216-218.
[15] 邵伟,金杭斌,顾竹影,等. 糖尿病合并脂肪肝临床特征分析. 中华消化杂志,2006,26（4）:268-269.
[16] Gholam PM,Flancbaum L,Machan JT,et al. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol,2007,102:399-408.
[17] Bujanda L,Elizabeth H,Mikel L,et al. Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol,2008,8:40.
[18] Taned C,Prasong T,Suwalee P,et al. Open-labeled pilot study of cysteine-rich whey protein isolate supplementation for nonalcoholic steatohepatitis patients. Hepatology,2009,24:1045-1050.

乳清蛋白对非酒精性脂肪性肝病大鼠肝脂肪变的防治作用^*

Protective effect of whey proteins on intrahepatic fatty infiltration in rats with nonalcoholic fatty liver disease

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[2]	徐飞, 李伟荣. 黄芪甲苷对CCL₄所致肝损伤大鼠的保护作用^*[J]. 实用肝脏病杂志, 2019, 22(6): 808-811.
[3]	高磊, 曹蕾, 王瑞芳, 冯丹丹, 薛娟. 人脐带间充质干细胞移植对酒精性肝损伤大鼠的保护作用^*[J]. 实用肝脏病杂志, 2019, 22(6): 812-815.
[4]	李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高. ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 848-851.
[5]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[6]	林秋香, 王雪雯, 黄祖雄, 潘晨. 灯盏花素对肝脏缺血再灌注损伤大鼠肝脏和肠黏膜屏障功能的保护作用*[J]. 实用肝脏病杂志, 2019, 22(5): 636-639.
[7]	石小龙, 杜睿, 秦革萍, 薛华燕, 张宏鑫. 七氟醚对脓毒症大鼠肝损伤的保护作用及其作用机制研究*[J]. 实用肝脏病杂志, 2019, 22(5): 640-643.
[8]	张胥磊, 杨庆余, 韩秋玉, 缪鋆鋆, 蔡仁诚, 马亦旻. 自拟中药治疗非酒精性脂肪性肝病患者血清炎症反应指标水平的变化*[J]. 实用肝脏病杂志, 2019, 22(5): 660-663.
[9]	王艳, 苏峰, 李园园, 李舒. 蜂毒溶血肽改善非酒精性脂肪肝大鼠肝组织脂肪沉积作用及其机制研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 474-477.
[10]	张兰华, 邵琴, 夏振娟. 非酒精性脂肪性肝病儿童血清25-（OH）D3和IL-17水平变化初步研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 522-525.
[11]	谢晓, 刘婷, 董志霞, 夏幼辰, 张启迪, 曲颖, 蔡晓波, 徐铭益, 陆伦根. FibroTouch检测肝脏受控衰减参数对肝脂肪变的诊断价值分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 526-529.
[12]	周丽云, 李校天, 李丽, 杨俊超. 1,25（OH）₂D₃通过调节miR-146a水平抑制大鼠肝纤维化的体内和体外观察[J]. 实用肝脏病杂志, 2019, 22(3): 333-336.
[13]	符亮, 吴冬冰, 纪新尊, 万鸿兴, 李文刚, 饶卉明, 钟静, 江婷婷. 超声定量评估非酒精性脂肪性肝病患者肝脏ARFI值对显著NASH的诊断价值分析[J]. 实用肝脏病杂志, 2019, 22(3): 377-380.
[14]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[15]	霍会芹,巩晓红,李正宏. 采用实时三维超声和斑点追踪技术评价非酒精性脂肪性肝病肝硬化患者右心功能^*[J]. 实用肝脏病杂志, 2019, 22(2): 244-247.